TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) are widely used in cancer treatment but face challenges with low response rates and eventual drug resistance.
• Tumor microenvironment complexity and cancer cell immune escape mechanisms, particularly immunosuppressive factors, contribute significantly to treatment failure.
• Triggering receptor expressed on myeloid cells-2 (TREM2), a transmembrane receptor, has emerged as a key player in pathology-induced immune signaling, negatively affecting anti-tumor immunity.

Purpose of the Study:

• To review recent advancements in understanding TREM2's role in cancer.
• To elucidate TREM2's regulation of tumor-associated immune signaling pathways.
• To highlight TREM2 as a potential novel target for enhancing cancer immunotherapy.

Main Methods:

• Literature review of recent studies on TREM2.
• Analysis of TREM2's involvement in immune signaling pathways within the tumor microenvironment.
• Evaluation of TREM2's impact on anti-tumor immune responses, including T cell proliferation.

Main Results:

• TREM2 acts as a crucial immune signaling hub within the tumor microenvironment.
• TREM2 plays a significant negative role in anti-tumor immunity by, for example, inhibiting T cell proliferation.
• These findings underscore the immunosuppressive functions of TREM2 in the context of cancer.

Conclusions:

• TREM2 is implicated in immune escape mechanisms within tumors.
• Targeting TREM2 presents a promising strategy for overcoming resistance to current cancer immunotherapies.
• Further research into TREM2's functions could lead to the development of more effective cancer treatments.